Table 2.
Analysis of associations between TNFA-308G/A, IL6-174G/C and IFNG + 874 T/A polymorphisms and risk of HAM/TSP development
| Polymorphisms | HAM/TSP | Asymptomatic | ||
|---|---|---|---|---|
| n (%) | n (%) | OR (IC:95%) | p-value | |
| TNFA-308G/A | ||||
| GG | 55 (82.1) | 69 (83.1) | 1 | 0.98 |
| GA | 12 (17.9) | 13 (15.7) | 1.16 (0.48–2.75) | |
| AA | 0 | 1 (1.2) | 0 (NA) | |
| GG (low) | 55 (82.1) | 69 (83.1) | 1 | 1 |
| GA + AA (high) | 12 (17.9) | 14 (16.9) | 1.08 (0.45–2.52) | |
| AA | 0 | 1 (1.2) | 1 | 1 |
| GA + GG | 67 (100) | 82 (98.8) | 0 (NA) | |
| Alleles | ||||
| G | 122 (91.0) | 151 (91.0) | 1 | 1 |
| A | 12 (9.0) | 15 (9.0) | 0.99 (0.44–2.19) | |
| IL6-174G/C | ||||
| GG | 48 (71.6) | 56 (68.3) | 1 | 0.88 |
| GC | 16 (23.9) | 24 (29.3) | 0.78 (0.37–1.62) | |
| CC | 3(4.5) | 2 (2.4) | 1.75 (0.28–13.7) | |
| CC (low) | 3 (4.5) | 2 (2.4) | 1 | 0.66 |
| GC + GG (high) | 64 (95.5) | 80 (97.6) | 0.53 (0.07–3.31) | |
| GG | 48 (71.6) | 56 (68.3) | 1 | 0.79 |
| GC + CC | 19 (28.4) | 26 (31.7) | 0.85 (0.42–172) | |
| Alleles | ||||
| G | 112(83.6) | 136 (82.9) | 1 | 1 |
| C | 22 (16.4) | 28 (17.1) | 0.95 (0.51–1.76) | |
| IFNG + 874 T/A | ||||
| AA (low) | 34 (50.7) | 34 (43.6) | 1 | 0.86 |
| AT (intermediate) | 26 (38.8) | 40 (51.3) | 0.65 (0.33–1.29) | |
| TT (high) | 7(10.4) | 4 (5.1) | 1.75 (0.48–7.20) | |
| AA | 34 (50.7) | 34 (43.6) | 1 | 0.49 |
| AT+TT | 33 (49.3) | 44 (56.4) | 0.75 (0.39–1.44) | |
| TT | 7 (10.4) | 4 (5.1) | 1 | 0.35 |
| AT+AA | 60 (89.6) | 74 (94.9) | 0.46 (0.12–1.61) | |
| Alleles | ||||
| A | 94 (70.1) | 108 (69.2) | 1 | 0.97 |
| T | 40 (29.9) | 48 (30.8) | 0.96 (0.58–1.58) | |
HAM/TSP HTLV-1 associated myelopathy tropical spastic paraparesis, Asymptomatic HTLV-1 patients, OR odds ration with confident interval, Chi-square 2 × 2 or 3 × 2 contingent tables, Fisher exact or Cochran-Armitage tests